
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 3, 2009

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction
of incorporation)

1-10730
(Commission
File Number)

04-2882273
(I.R.S. Employer
Identification No.)

400 Wood Road
(Address of principal executive offices)

02184
(Zip Code)

Registrant's telephone number, including area code **781-848-7100**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

TABLE OF CONTENTS

[Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION](#)

[Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)

[EX-99.1](#)

[Table of Contents](#)

Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 3, 2009 Haemonetics Corporation (the "Company") issued a press release announcing financial results for the first quarter ended June 27, 2009. A copy of the release is furnished with this report as exhibit 99.1.

The information in this current report on Form 8-K and the exhibit attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated August 3, 2009 announcing financial results for the first quarter ended June 27, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION
(Registrant)

Date: August 3, 2009

/s/ Christopher Lindop

Christopher Lindop, Vice President
and Chief Financial Officer

EXHIBIT INDEX

99.1 Press Release issued by Haemonetics Corporation on August 3, 2009.

HAEMONETICS CORPORATION 400 Wood Road, Braintree, Massachusetts 02184 (781) 356-9517 investor@haemonetics.com

FOR RELEASE:

Date: August 3, 2009
 Time: 8:00 am Eastern

CONTACT:

Julie Fallon
 Tel. (781) 356-9517
 Alternate Tel. (617) 320-2401
fallon@haemonetics.com

**Haemonetics Reports Double Digit Growth in Earnings for First Quarter Fiscal 2010
 Company Affirms Full Year Guidance**

Braintree, MA, August 3, 2009 – Haemonetics Corporation (NYSE: HAE) reported first quarter GAAP net revenues of \$154 million, up 7%; net income of \$18 million, up 26%, and earnings per share of \$0.69, up 28%. Excluding restructuring charges in fiscal 2009 which did not recur in fiscal 2010, adjusted first quarter net income growth was 16%, and adjusted earnings per share growth was 18%.¹

Haemonetics ended the first quarter with \$174 million in cash and \$22 million of debt, and generated \$5 million of free cash flow.

Brian Concannon, Haemonetics' President and CEO, said, "I'm extremely pleased with our start to fiscal 2010. We continue to deliver strong financial results while making excellent progress in execution to our full year goals for blood management solutions. Haemonetics remains extremely well positioned in the current economic environment."

In addition to revenue and earnings growth, Haemonetics reported strong margin expansion in the quarter. Gross margin grew 310 basis points to 53.8%. Despite incremental expenses from acquired businesses, the Company managed operating expenses to \$57 million, up 9% as adjusted, leading to operating income of \$26 million, up 24% as adjusted. Operating margin was 17.1%, up 240 basis points as adjusted.¹

The Company also affirmed its full year guidance of 8-11% revenue growth, operating income growth of 12-15%, and earnings per share in a range of \$2.75 to \$2.85.

STRATEGIC AND SEGMENT GROWTH HIGHLIGHTS¹

Haemonetics continues to make progress expanding its business. The Company reported the following highlights:

- Early positive results with the new Express™ plasma collection protocol consistently achieving a reduction in plasma donation time of more than 20%
- Success with its recent acquisition, Neoteric Technologies, signing two new contracts for the BloodTrack® system
- Progress implementing customized blood management solutions with 3 hospitals currently engaged in Haemonetics' InSight™ program and 13 hospitals engaged in Haemonetics' Impact program (InSight accounts leverage a full range of Haemonetics' devices and services to realize economic and clinical benefits across an entire hospital system; Impact accounts leverage a specific device implementation and measure economic benefit for discreet departments)

As noted, Haemonetics' first quarter fiscal 2010 reported revenues were \$154 million, up 7%. Excluding the effects of currency, first quarter net revenues grew 6.2%. Reported revenues break down as follows:

Plasma disposables revenue was \$59 million for the quarter, up 26%. Haemonetics' plasma business benefited from long-term contract implementation, global growth in plasma collections, and pricing increases. Haemonetics expects its plasma business will continue to be an ongoing revenue growth driver for the Company and increased its annual Plasma revenue growth estimate to 19-22% growth.

Platelet disposables (formerly reported as Blood Bank disposables) revenue was \$34 million for the quarter, down 4%. The Platelet business was impacted by two, temporary factors: currency devaluations in Korea which put pressure on Haemonetics' distributor's sales and distributor changes in key markets. The planned distributor changes are expected to have a positive impact on the full year. Additionally, Japan platelet sales were down modestly. Haemonetics said it now expects full year Platelet revenue growth in a range of 0-2%.

Red Cell disposables revenue was \$12 million for the quarter, level with the first quarter fiscal 09. Higher red cell inventories, stemming partly from the reduction in elective surgeries, reduced demand for Haemonetics' automated red cell collection systems. Haemonetics is seeing growth with some key customers and believes that once blood inventories stabilize, the Company can capitalize on red cell growth opportunities. In fact, in July, blood bank customers were beginning to report red cell shortages. Haemonetics double red cell collection technology positively impacts blood supplies because it can collect two units of red cells from one donor. Haemonetics affirmed its annual Red Cell revenue growth estimate of 6-8%.

Software Solutions revenue was \$8 million for the quarter, up 17%. Because Haemonetics provides the information management platforms for plasma centers on a per donor fee, increased plasma collections positively impacted the Software Solutions line. Additionally, Haemonetics benefited from sales from its acquired companies, Altivation® and Neoteric, whose sales were not included in the first quarter of last fiscal year. Haemonetics affirmed its annual Software Solutions revenue growth rate estimate of 9-13%.

Haemonetics' Hospital disposable systems were impacted by the current economic environment. Fewer elective surgeries impacted the Surgical and OrthoPAT® product lines, and reduced hospital spending on equipment impacted a portion of the Diagnostics line. By product line, Surgical revenues were \$17 million, up 1%; OrthoPAT revenues were \$9 million, down 2%, and Diagnostics revenues were \$5 million, down 2%. However, excluding TEG® equipment sales, Diagnostics disposables revenues grew 9%. Haemonetics estimates revenue will be flat in Surgical and expects growth of 5-7% in OrthoPAT and 15-20% in Diagnostics for the year.

Mr. Concannon added, "Haemonetics' business solutions address a critical need in healthcare to lower costs and improve patient care, and many economic factors favor our value proposition. We are well positioned to continue to deliver strong operating results with 8-11% revenue growth and 12-16% EPS growth in the year."

Haemonetics has posted several items on its website: fiscal 2010 guidance; income scenarios reflecting guidance ranges; and potential fiscal 2010 product line growth. The information is posted at <http://www.haemonetics.com/site/content/investor/guidance.asp>.

CONFERENCE CALL

Haemonetics will host a webcast on Monday, August 3rd at 10:00 am Eastern to discuss these results. Interested parties can participate at <http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=2323195>.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at <http://www.haemonetics.com>.

This release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.

¹ A reconciliation of GAAP to adjusted financial results is included at the end of the financial sections of this press release as well as on the web at <http://www.haemonetics.com/investors>. In the first quarter of fiscal 2009, Haemonetics incurred \$1.9 million in pre-tax restructuring costs. Haemonetics incurred no restructuring costs in the first quarter of fiscal 2010.

Haemonetics Corporation Financial Summary
(Unaudited data in thousands, except per share data)
Consolidated Statements of Income for the First Quarter FY10

	6/27/09 As Reported	6/28/08 As Reported	% Inc/(Dec) vs Prior Year
NET REVENUES	\$ 154,087	\$ 144,116	6.9%
Gross Profit	82,943	73,037	13.6%
R&D	6,777	5,844	16.0%
S, G&A	49,839	47,859	4.1%
Operating Expenses	<u>56,616</u>	<u>53,703</u>	5.4%
Operating Income	26,327	19,334	36.2%
Interest Expense	(214)	(24)	791.7%
Interest Income	157	654	(76.0%)
Other (Expense)/Income, Net	<u>(335)</u>	<u>375</u>	<u>(189.3%)</u>
Income Before Taxes	25,935	20,339	27.5%
Tax Expense	<u>7,862</u>	<u>5,998</u>	31.1%
NET INCOME	\$ 18,073	\$ 14,341	26.0%
Net Income per Common Share Assuming Dilution	\$ 0.69	\$ 0.54	27.5%
Weighted Average Number of Shares			
Basic	25,658	25,607	
Diluted	26,201	26,517	
			Inc/(Dec) vs prior year profit margin %
Profit Margins:			
Gross Profit	53.8%	50.7%	3.1%
R&D	4.4%	4.1%	0.3%
S,G&A	32.3%	33.2%	(0.9%)
Operating Income	17.1%	13.4%	3.7%
Income Before Taxes	16.8%	14.1%	2.7%
Net Income	11.7%	10.0%	1.7%

Revenue Analysis for the First Quarter FY10

	6/27/09 As Reported	First Quarter 6/28/08 As Reported	% Inc/(Dec) vs Prior Year
Revenues by Geography			
United States	\$ 75,013	\$ 65,789	14.0%
International	\$ 79,074	\$ 78,327	1.0%
Net Revenues	<u>\$154,087</u>	<u>\$144,116</u>	6.9%
Disposable Revenues by Product Family			
Plasma Disposables	\$ 58,869	\$ 46,868	25.6%
Blood Bank Disposables			
Platelet	\$ 34,307	\$ 35,659	(3.8%)
Red Cell	\$ 11,779	\$ 11,842	(0.5%)
	<u>\$ 46,086</u>	<u>\$ 47,501</u>	(3.0%)
Hospital Disposables			
Surgical	\$ 17,425	\$ 17,269	0.9%
OrthoPAT	\$ 8,584	\$ 8,796	(2.4%)
Diagnostics	\$ 4,997	\$ 5,094	(1.9%)
	<u>\$ 31,006</u>	<u>\$ 31,159</u>	(0.5%)
Subtotal	\$135,961	\$125,528	8.3%
Software Solutions	\$ 8,454	\$ 7,258	16.5%
Equipment & Other	\$ 9,672	\$ 11,330	(14.6%)
Net Revenues	<u>\$154,087</u>	<u>\$144,116</u>	6.9%

Consolidated Balance Sheets

	Period ending	
	6/27/09	3/28/09
Assets		
Cash & Cash Equivalents	\$173,822	\$156,721
Accounts Receivable, Net	114,161	113,598
Inventories, Net	76,097	76,522
Other Current Assets	32,074	35,552
Total Current Assets	396,154	382,393
Net PP&E	150,387	137,807
Other Assets	145,402	129,493
Total Assets	\$691,943	\$649,693
	Period ending	
	6/27/09	3/28/09
Liabilities & Stockholders' Equity		
S/T Debt & Current Maturities	\$ 17,200	\$ 695
Other Current Liabilities	86,852	92,168
Total Current Liabilities	104,052	92,863
Long-Term Debt	5,160	5,343
Other Long-Term Liabilities	18,878	11,603
Stockholders' Equity	563,853	539,884
Total Liabilities & Equity	\$691,943	\$649,693

FREE CASH FLOW RECONCILIATION

	Three Months Ended	
	6/27/09	6/28/08
GAAP CASH FLOW FROM OPERATIONS	\$ 25,706	\$ 13,842
Capital Expenditures	(21,204)	(12,395)
Proceeds from Sale of Property, Plant and Equipment	201	2,476
Net Investment in Property, Plant and Equipment	(21,003)	(9,919)
Free Cash Flow	\$ 4,703	\$ 3,923

Haemonetics Corporation Financial Summary
Reconciliation of Non-GAAP Measures

Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.

These measures are used by management to monitor the financial performance of the business, inform business decision making, and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below, we have removed restructuring costs from our GAAP expenses. These restructuring costs result from a significant transformation of our business during our fiscal years 2009 and 2008. This transformation resulted in the formation of a shared service center in Europe, exiting various offices across Europe and Japan and, most recently, in repositioning our technical operations organization. We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.

Non-GAAP Gross Profit

The use of these non-GAAP measures allows management to monitor the level of total gross profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

Non-GAAP S,G&A and Non-GAAP Operating Expenses

The use of this non-GAAP measure allows management to monitor the ongoing level of spend that is necessary to support the business in a period when we are not transforming our business or completing an acquisition of in-process research and development. We establish our budgets, forecasts, and performance targets excluding these costs.

Non-GAAP Operating Income and Non-GAAP Income before Income Taxes

The use of these non-GAAP measures allows management to monitor the level of operating and total pre-tax profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

Non-GAAP Net Income and Earnings per Share

The use of these non-GAAP measures allows management to monitor the level of net income and earnings per share excluding both the costs of our business transformation, as well as any related tax effects. We establish our budgets, forecasts, and performance targets on this basis.

Reconciliation of Non-GAAP Measures for the First Quarter of FY10 and FY09

	06/27/09	06/28/08
Non-GAAP Gross Profit		
GAAP Gross Profit	\$ 82,943	\$ 73,037
Restructuring Costs	0	72
Non-GAAP Gross Profit	<u>\$ 82,943</u>	<u>\$ 73,109</u>
Non-GAAP S, G&A		
GAAP S, G&A	\$ 49,839	\$ 47,859
Restructuring Costs	0	(1,781)
Non-GAAP S, G&A	<u>\$ 49,839</u>	<u>\$ 46,078</u>
Non-GAAP Operating Expenses		
GAAP Operating Expenses	\$ 56,616	\$ 53,703
Restructuring Costs	0	(1,781)
Non-GAAP Operating Expenses	<u>\$ 56,616</u>	<u>\$ 51,922</u>
Non-GAAP Operating Income		
GAAP Operating Income	\$ 26,327	\$ 19,334
Restructuring Costs	0	1,853
Non-GAAP Operating Income	<u>\$ 26,327</u>	<u>\$ 21,187</u>
Non-GAAP Income Before Taxes		
GAAP Income Before Taxes	\$ 25,935	\$ 20,339
Restructuring Costs	0	1,853
Non-GAAP Income Before Taxes	<u>\$ 25,935</u>	<u>\$ 22,192</u>
Non-GAAP Net Income		
GAAP Net Income	\$ 18,073	\$ 14,341
Restructuring Costs	0	1,853
Tax Benefit Associated With Restructuring Costs	0	(650)
Non-GAAP NET INCOME	<u>\$ 18,073</u>	<u>\$ 15,544</u>
Non-GAAP Net Income Per Common Share Assuming Dilution		
GAAP Net Income per Common Share Assuming Dilution	\$ 0.69	\$ 0.54
Restructuring Costs After Tax per Common Share Assuming Dilution	\$ 0.00	\$ 0.05
Non-GAAP Net Income per Common Share Assuming Dilution	<u>\$ 0.69</u>	<u>\$ 0.59</u>